The European Patent Office recently issued an important decision that opens new doors in the biotechnology market, in particular those using CRISPR-Cas9. CRISPR-Cas9 is this tool used like a molecular scissors to cut and replace DNA sequences precisely and specifically.

This complex is composed of an RNA sequence recognizing a specific target DNA site and a nuclease (an enzyme for cutting nucleic acids), the Case 9. The repair of this DNA is then free to be random or directed by humans with the addition of a DNA sequence (template) to the CRISPR-Cas9 complex.

This decision on the European patent EP 2771468 opens the door to the exploitation and marketing of this technology on the European territory. Other patents and patent applications relate to this technology, which is revolutionising genetics and modern medicine. This is why increased vigilance on the freedom to exploit your inventions using CRISPR-Cas9 is required.

Protecting your inventions, know-how, corpus etc. is one of the missions offered by Erganeo, which accompanies you from the declaration of invention, through the patent application, to international extensions. Find out more

For example, Erganeo is supporting the start-up company Cogith, which is developing an original treatment for liver cancer using gene/cellular therapy and immunotherapy.

This is a field in which the advances and stakes are high, since they could lead to regenerative medicine, a real revolution for living better and longer. 

-> Want to know more? Find HERE a video presenting the CRISPR-Cas9 technology.